Capital-FORCE Enters ETF Market with Acquisition of Two IBD Funds

LOS ANGELES, CA – April 17, 2026 – The competitive landscape of exchange-traded funds has a new contender as Capital-FORCE ETF Trust officially enters the market through a strategic acquisition. Following shareholder approval announced on April 10, the California-based firm is set to take over two established funds from Innovator ETFs®: the Innovator IBD® 50 ETF (FFTY) and the Innovator IBD® Breakout Opportunities ETF (BOUT).

This move marks a significant debut for Capital-FORCE and its affiliated SEC-registered investment adviser, M2 Financial LLC. Rather than building a brand from the ground up, the firm has opted to acquire funds with an existing track record and a well-regarded investment methodology. The reorganization, expected to be finalized by the end of April 2026, will see the two funds rebranded as the CapForce IBD® 50 ETF and the CapForce IBD® Breakout Opportunities ETF, respectively.

A New Player's Calculated Entry

For Capital-FORCE, this acquisition is a calculated first step into a crowded and dynamic industry. The firm's stated philosophy centers on creating transparent, dynamic portfolios designed for “real-world markets” and empowering investors to act decisively during periods of volatility. By acquiring FFTY and BOUT, Capital-FORCE gains an immediate foothold in the popular thematic and factor-based investing segment.

This strategy allows the firm to bypass the lengthy and often costly process of launching new products and building assets from scratch. Instead, it inherits funds with a combined asset base of nearly $100 million and an established investor following. The move is indicative of a broader trend where new entrants seek to accelerate their growth by acquiring existing product lines, particularly those with a strong brand association.

The reorganization was approved by the Board of Trustees of the Innovator ETFs® Trust on January 21, 2026, before gaining the necessary shareholder approval this month. The transaction is structured to be tax-free for existing shareholders, who will see their holdings automatically converted into shares of the new CapForce funds of equal net asset value.

A Closer Look at the Acquired Funds

The two ETFs at the center of this deal offer distinct but related exposures to growth-oriented equities, backed by the well-known Investor's Business Daily (IBD) brand.

The Innovator IBD® 50 ETF (FFTY), the larger of the two with approximately $82.3 million in assets, is designed to track the IBD® 50 Index. This index identifies 50 leading U.S. growth stocks based on a proprietary, rules-based system that evaluates factors like earnings growth, sales momentum, and stock price performance. Since its inception in 2015, the fund has offered investors a direct way to invest in IBD's top-ranked growth names. While it posted a strong one-year return of 38%, it also faced a recent six-month pullback, and Morningstar assigned it a "Negative" Medalist Rating as of February 2026, citing process and management concerns that Capital-FORCE will now be tasked with addressing.

The Innovator IBD® Breakout Opportunities ETF (BOUT) is a smaller, more tactical fund with around $14.8 million in assets. It seeks to capture stocks that are experiencing price "breakouts" from established trading ranges, a strategy that aims to capitalize on emerging momentum. Unlike the passively managed FFTY, BOUT offers a more dynamic approach to growth investing. Notably, Morningstar recently upgraded BOUT's rating to "Bronze" from "Neutral" in March 2026, citing a recent fee cut, which may signal positive momentum for the strategy as it transitions to its new home.

The Enduring Power of the IBD® Brand

A crucial element of this acquisition is the continuity of the Investor's Business Daily brand. Founded by legendary investor William J. O'Neil, IBD is renowned for its data-driven approach to stock selection, most famously encapsulated in the CAN SLIM methodology. This system combines fundamental analysis of a company's earnings and sales with technical analysis of its stock's price and volume trends.

The decision to retain "IBD" in the new fund names—CapForce IBD® 50 ETF and CapForce IBD® Breakout Opportunities ETF—is a clear signal that the underlying investment methodologies will remain intact. Capital-FORCE will likely continue to license the IBD® 50 Index and its associated rules-based selection process. This brand continuity is critical for retaining the loyalty of investors who have specifically chosen these ETFs for their adherence to O'Neil's proven growth investing principles. For these investors, the IBD name is synonymous with a disciplined, research-backed strategy for identifying market-leading companies.

Implications for Investors and the Market

For current shareholders of FFTY and BOUT, the primary change will be the name on the letterhead. The tax-free nature of the reorganization ensures a smooth transition without triggering a taxable event. However, investors will be watching closely for any changes to the funds' expense ratios. Both ETFs currently carry an expense ratio of 0.80%, and with the industry-wide trend of fee compression, there may be pressure on Capital-FORCE to adjust these fees to remain competitive.

This acquisition also reflects the ongoing consolidation and evolution within the ETF industry. Innovator Capital Management, which is divesting these funds, was itself largely acquired by Goldman Sachs in late 2025, primarily for its leadership in Buffer ETFs™. This reorganization allows Innovator to streamline its focus on its core outcome-based strategies while providing Capital-FORCE with a turnkey solution to enter the thematic growth space.

By taking the helm of these IBD-branded products, Capital-FORCE is immediately positioned to compete against a host of thematic and factor-based ETFs from industry giants like BlackRock and Fidelity, as well as other specialized providers. The success of this new chapter will depend on Capital-FORCE's ability to effectively manage the funds, maintain the integrity of the IBD strategies, and communicate its value proposition to both existing and prospective investors in a highly competitive market.